As per our report, the size of the global epigenetics market is predicted to grow USD 784.1 million in 2020 and will reach USD 1499.0 million by 2025, showcasing a CAGR of 13.84 % during the forecast period.
Epigenetics is the study of change in behaviour of organisms by modification of gene expression rather than a change in genetic code itself. Genes will get turned off or turned on depending on the circumstances, interactions, etc. These turning on and off of genes differ in most of the humans making humans unique. Some of these traits are passed down to future generations as heritable traits. The study of this entire mechanism is called Epigenetics. For instance, epigenetic change is DNA methylation, where the addition of a methyl group to part of the DNA molecule prevents certain gene expressions. This type of epigenetic change of DNA methylation is associated with cancer development and progression. Scientist claim that the genetical changes such a tumour suppression helps prevent cancer from one generation to other. Also, in many other aspects, epigenetics methodology is contributing to help diagnose diseased conditions earlier and prevent them for future generations.
MARKET DRIVERS
Rising Prevalence of Cancer and Technological Advancements in the Cancer Treatment are majorly driving the growth to the Global Epigenetics Market.
Globally, the number of individuals who have Cancer has increased significantly. There are about 18 million population suffering from Cancer. The primary cancer types are Cancer of the oral cavity and pharynx, Breast Cancer, Bowel Cancer, Lung cancer, prostate cancer. Similarly, in that, 33% caused because of smoking habits. Obesity and Overweight is the second biggest cause of cancer after smoking.
The origin and progression of cancer are associated with epigenetic changes such as dysregulation of DNA methylation. Epigenetics offers new ways to develop therapeutic approaches to reverse cancer dysregulation. Several cancer research trials are currently underway using epigenetics techniques; massive investments are being made to support these workers.
The global epigenetics market is further driven by the increasing funding in R&D and increasing frequency of research activities in this field.
MARKET RESTRAINTS
The dearth of the skilled person in utilizing the systems in diagnostic centres and the high costs associated with the instruments and treatment options are the major factors restraining the growth of the epigenetics market.
Difficulties in getting approvals from the government organizations for innovative products, lack of reimbursement schemes by the government, especially in undeveloped countries and lack of awareness of different epigenetic techniques in the rural areas are further expected to limit the market growth.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Analysed |
By Anatomical Location, Consumable Type, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Analysed |
North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
This research report on the Global Epigenetics Market has been segmented and sub-segmented based on the anatomical location, consumable type and Region.
Epigenetics Market - By Product:
Based on the product, in 2019, the enzymes segment held the highest shares in the global market, followed by the Instruments & Consumables segment. Growing awareness over the availability of different techniques is elevating the demand of this segment. However, the Kits and reagents segment is projected to have a significant growth rate in the forecast period.
Epigenetics Market - By Research Area:
Throughout last year, Oncology led the overall market, accounting for 69.6% of total revenue. Growing the prevalence of cancer worldwide is projected to be a high impact making factor on the market, along with increased cancer deaths. Additionally, due to the introduction of new products and potential future promotion of goods already in the pipeline, this segment is expected to gain a significant share of revenue throughout the forecast period.
The developmental biology segment is expected to shine well in the market due to the increasing scale of research centres. COVID-19 is impacting largely on the growth of this segment as researchers are focused on developing a vaccine for this novel disease. The oncology segment also has a significant growth rate from the past few years. On-going research on the next-generation sequencing is lavishing the growth rate of this segment. Drug delivery is to have slow growth opportunities in the forecast period.
Epigenetics Market - By Enzymes:
Based on enzymes, DNA-Modifying Enzymes segment accounted for the majority of the shares in the market in 2019. Increasing support from the government authorities through funds is a major factor fueling the demand of the market. Protein-modifying enzymes are next to DNA-modifying enzymes in holding the highest shares of the market. Prevalence to develop innovative drugs or vaccines to promote quality treatment procedure across the world is greatly influencing the growth rate of the market. The RNA-modifying enzymes segment is expected to have the highest CAGR in the coming years.
Epigenetics Market - By Instruments & Consumables:
The qPCR segment was the leader in the market among different types of instruments and consumables and held the highest shares of the market in 2019. Raising awareness through campaigns and digital platforms in the medical sector is impacting positively on the growth of the market. Next-generation sequences are following qPCR segment with the increasing studies on genomic. Mass spectrometers segment and sonicators segments are to have prominent growth rate in foreseen years.
Epigenetics Market - By KITS:
Based on KITS, Bisulfate conversion kits segment is having the highest shares of the market. Public and private organizations are largely investing in the biotechnology field, which is a common factor for the market to grow. Chip sequence kits and RNA sequencing kits are next to bisulfate conversion kits segment by owing to growing demand to promote high-quality services to the patients. Whole-genome amplification kits and 5-HMC and 5-MC Analysis KITS segments are inclined to have the highest growth rate in a few years.
Epigenetics Market - By Reagents:
Based on reagents, the antibodies reagents segment is ruling with dominant shares of the market. Due to rising cases of COVID-19, clinical trials are put on the fast track to develop a vaccine. This is propelling the demand for this segment to the extent. Buffers and histones segments are expected to lead the market shares in the coming years. Constant economic growth in both developed and developing countries is ascribed to bolster the demand of these segments. Magnetic beads and primers segment is to have a steady pace in the forecast period.
Epigenetics Market - By Region:
Based on Region, North America dominated the global market in 2019. The growth of the epigenetics market in North America is majorly driven by the massive presence of major players in North America; the government makes significant investments for research and development and rapid developments in healthcare infrastructure. In North America, there is a huge demand for insulin, antibodies, mammalian proteins and vaccines produce industrially and are expected to help the market to climb new growth heights. In the future, the North American market will have many opportunities for market leaders and new players.
In Europe, the epigenetics market is expected to have promising growth in the coming years. More than 3.7 million new cases and 1.9 million cancer deaths occur in the European Region as per the data given by the WHO. The European Region is the second-largest region in the global epigenetics market, which has the highest mortality rate of cancer. The rising patient count and the incidence of cancer are expected to propel the market growth in this region.
The Asia-pacific market is expected to grow at the highest CAGR during the forecast period owing to the developing countries like India and China, and increasing R&D spending by companies.
Companies playing a leading role in the global epigenetics market profiled in this report are Abcam PLC, Illumina, Inc., QIAGEN N.V., Merck & Co, New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif, Diagenode, Inc. and Zymo Research Corporation.
RECENT MARKET DEVELOPMENTS
On February 6, 2018, QIAGEN began epigenetic breast cancer screening in Europe in February 2018.
On November 23, 2015, Abcam completed the acquisition of AxioMx to access new opportunities for growth and expand the leadership of antibodies. The expansion of its business in the global market for epigenetics.
On April 7, 2014, Roche and Oryzon Genomics SA announced a global partnership to study, develop and market Lysine Specific Demethylase-1 (LSD1; KDM1A) inhibitors, an epigenetic modulator that controls gene expression.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Enzymes
5.1.2.1 DNA-Modifying Enzymes
5.1.2.2 Protein-Modifying Enzymes
5.1.2.3 RNA-Modifying Enzymes
5.1.3 Instruments & Consumables
5.1.3.1 Mass Spectrometers
5.1.3.2 Next-Generation Sequencers
5.1.3.3 QPCR
5.1.3.4 Sonicators
5.1.3.5 Others
5.1.4 KITS
5.1.4.1 Bisulfite Conversion KITS
5.1.4.2 Chip-Sequence KITS
5.1.4.3 RNA Sequencing KITS
5.1.4.4 Whole-Genome Amplification KITS
5.1.4.5 5-HMC and 5-MC Analysis KITS
5.1.4.6 Others
5.1.5 Reagents
5.1.5.1 Antibodies
5.1.5.2 buffers
5.1.5.3 Histones
5.1.5.4 Magnetic Beads
5.1.5.5 Primers
5.1.5.6 Others
5.1.6 Y-o-Y Growth Analysis, By Product
5.1.7 Market Attractiveness Analysis, By Product
5.1.8 Market Share Analysis, By Product
5.2 Research Area
5.2.1 Introduction
5.2.2 Developmental Biology
5.2.3 Oncology
5.2.4 Drug Delivery
5.2.5 Y-o-Y Growth Analysis, By Research Area
5.2.6 Market Attractiveness Analysis, By Research Area
5.2.7 Market Share Analysis, By Research Area
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Research Area
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Research Area
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Research Area
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abcam plc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Illumina, Inc.
8.3 QIAGEN N.V.
8.4 Merck & Co.
8.5 New England Biolabs, Inc.
8.6 Zymo Research Corporation
8.7 Sigma-Aldrich Corporation
8.8 Thermo Fisher Scientific, Inc.
8.9 Active Motif
8.10 Diagenode, Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
